Summit Therapeutics Inc
NASDAQ:SMMT

Watchlist Manager
Summit Therapeutics Inc Logo
Summit Therapeutics Inc
NASDAQ:SMMT
Watchlist
Price: 26.29 USD -1.5% Market Closed
Market Cap: 19.5B USD

EV/EBIT
Enterprise Value to EBIT

-90.7
Current
-30.7
Median
5.7
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-90.7
=
Enterprise Value
19.1B USD
/
EBIT
-211m USD
EBIT Growth EV/EBIT to Growth
US
Summit Therapeutics Inc
NASDAQ:SMMT
Average EV/EBIT: 18.8
Negative Multiple: -90.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 947.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
28%
0.8
US
Amgen Inc
NASDAQ:AMGN
18.6
19%
1
US
Gilead Sciences Inc
NASDAQ:GILD
14.9
12%
1.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -560.5 N/A N/A
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.1
17%
1.2
AU
CSL Ltd
ASX:CSL
20.8
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.9
10%
1.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -321.9 N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.5 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-61.2
2-Years Forward
EV/EBIT
-48.1
3-Years Forward
EV/EBIT
-46.6